Boston Scientific Corporation, headquartered in Marlborough, Massachusetts, USA, is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties. The company's products are designed to diagnose and treat complex cardiovascular, digestive, oncological, neurological, urological, and respiratory conditions. Boston Scientific is committed to transforming lives through innovative medical solutions that improve patient health. With a presence in over 100 countries, the company collaborates with healthcare professionals worldwide to advance the quality of patient care.
The FDA published a letter to healthcare providers stating that, based on its review of the totality of the available data and analyses, the excess risk of mortality associated with paclitaxel-coated devices to treat peripheral arterial disease (PAD) is no longer supported.